February 13, 2018 / 9:22 PM / 11 days ago

BRIEF-Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Feb 13 (Reuters) - Exelixis Inc:

* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA

* EXELIXIS INC - ‍EXELIXIS PLANS TO INITIATE A PIVOTAL PHASE 3 TRIAL LATER THIS YEAR​

* EXELIXIS INC - ‍54 PERCENT OBJECTIVE RESPONSE RATE AND 43 PERCENT STABLE DISEASE OBSERVED AMONG 35 EVALUABLE PATIENTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below